Roger Mills

4.8k total citations · 3 hit papers
20 papers, 3.3k citations indexed

About

Roger Mills is a scholar working on Neurology, Psychiatry and Mental health and Epidemiology. According to data from OpenAlex, Roger Mills has authored 20 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 6 papers in Psychiatry and Mental health and 4 papers in Epidemiology. Recurrent topics in Roger Mills's work include Parkinson's Disease Mechanisms and Treatments (8 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (4 papers). Roger Mills is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (8 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (4 papers). Roger Mills collaborates with scholars based in United States, United Kingdom and France. Roger Mills's co-authors include Penelope Ward, Hilde Williams, Nelson Kinnersley, Frederick G. Hayden, John J. Treanor, Frederick G. Hayden, Clive Ballard, Jeffrey L. Cummings, Anne Corbett and Rick A. Barbarash and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Roger Mills

20 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

2000 781 citations John J. Treanor, Frederick G. Hayden et al. JAMA profile →
Oral oseltamivir treatment of influenza in children

2001 541 citations Richard J. Whitley, Frederick G. Hayden et al. The Pediatric Infectious Disease Journal profile →
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

2013 481 citations Jeffrey L. Cummings, Stuart Isaacson et al. The Lancet profile →

Peers

Countries citing papers authored by Roger Mills

Since Specialization

Citations

This map shows the geographic impact of Roger Mills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Mills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Mills more than expected).

Fields of papers citing papers by Roger Mills

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Mills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Mills. The network helps show where Roger Mills may publish in the future.

Co-authorship network of co-authors of Roger Mills

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Mills. A scholar is included among the top collaborators of Roger Mills based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Mills. Roger Mills is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm 2024 ·Movement Disorders ·(unknown), Hodam Kim, Dongdong Chen, (unknown), Ashok Reddy Dinasarapu, Laura Scorr, Woon‐Hong Yeo, David Peterson, Hilde Williams, (unknown), Roger Mills, Hyder A. Jinnah	5
2	Drug repositioning and repurposing for Alzheimer disease 2020 ·Nature Reviews Neurology ·Clive Ballard, Dag Aarsland, Jeffrey L. Cummings, John T. O’Brien, Roger Mills, José Luís Molinuevo, Tormod Fladby, Gareth Williams, (unknown), Anne Corbett, Janet Sultana	132
3	Psychosis in Alzheimer’s Disease 2020 ·Current Neurology and Neuroscience Reports ·Clive Ballard, Helen C. Kales, Constantine G. Lyketsos, Dag Aarsland, Byron Creese, Roger Mills, Hilde Williams, Robert A. Sweet	35
4	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis 2015 ·Journal of the American Medical Directors Association ·Clive Ballard, Stuart Isaacson, Roger Mills, Hilde Williams, Anne Corbett, Bruce Coate, Rajesh Pahwa, Olivier Rascol, David J. Burn	49
5	Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies 2015 ·Parkinsonism & Related Disorders ·Roger Mills, Stuart Isaacson, (unknown), Joaquim J. Ferreira, (unknown), Tihomir Ilić, Kathy Chi‐Burris, Hilde Williams	6
6	Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD Psychosis: Analysis of an integrated Phase 3 placebo-controlled dataset 2015 ·Parkinsonism & Related Disorders ·Roger Mills, Joseph H. Friedman, William G. Ondo, Rajesh Pahwa, Kevin J. Black, Kathy Chi‐Burris, Hilde Williams	2
7	Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies 2015 ·Parkinsonism & Related Disorders ·Roger Mills, Stuart Isaacson, (unknown), Joaquim Ferreira, (unknown), Tihomir Ilić, Kathy Chi‐Burris, Hilde Williams	3
8	On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis 2014 ·Neurochemical Research ·Uli Hacksell, Ethan S. Burstein, Krista McFarland, Roger Mills, Hilde Williams	111
9	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial breakdown → 2013 ·The Lancet ·Jeffrey L. Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi‐Burris, Anne Corbett, Rohit Dhall, Clive Ballard	481
10	Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020) 2013 ·Journal of the Neurological Sciences ·Joanne Cummings, Stuart Isaacson, Roger Mills, Hywel C Williams, Kathy Chi‐Burris, Rohit Dhall, Clive Ballard	12
11	O4–05–04: Antipsychotic efficacy and good tolerability in a Phase III placebo‐controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP‐103–020) 2013 ·Alzheimer s & Dementia ·Clive Ballard, Roger Mills, Hilde Williams, Kathy Chi‐Burris, Daun Bahr, Jeffrey L. Cummings	1
12	Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis 2012 ·Parkinsonism & Related Disorders ·Tiffini Voss, Daun Bahr, Jeffrey L. Cummings, Roger Mills, Bernard Ravina, Hilde Williams	61
13	2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP) 2011 ·Parkinsonism & Related Disorders ·Roger Mills, Daun Bahr, Hywel C Williams	4
14	Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis 2009 ·Neuropsychopharmacology ·Herbert Y. Meltzer, Roger Mills, (unknown), Hilde Williams, Ann Johnson, Daun Bahr, Joseph H. Friedman	224
15	Co-therapy with pimavanserin and risperidone 2 mg provides an improved clinical profile 2008 ·Schizophrenia Research ·Herbert Y. Meltzer, (unknown), Hélio Elkis, (unknown), M. Rosenthal, Roger Mills	2
16	Oral oseltamivir treatment of influenza in children breakdown → 2001 ·The Pediatric Infectious Disease Journal ·Richard J. Whitley, Frederick G. Hayden, Keith S. Reisinger, Nancy L. Young, Regina Dutkowski, David Ipe, Roger Mills, Penelope Ward	541
17	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza breakdown → 2000 ·JAMA ·John J. Treanor, Frederick G. Hayden, (unknown), Rick A. Barbarash, Robert Bettis, Dennis Riff, Sudeep Singh, Nelson Kinnersley, Penelope Ward, Roger Mills, (unknown)	781
18	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza 1999 ·New England Journal of Medicine ·Frederick G. Hayden, Robert L. Atmar, M. Schilling, Casey Johnson, Donald M. Poretz, Dávid Paár, Les Huson, Penelope Ward, Roger Mills	384
19	Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza 1999 ·JAMA ·Frederick G. Hayden, John J. Treanor, Richard Fritz, Monica Lobo, Robert F. Betts, Madeline R. Miller, Nelson Kinnersley, Roger Mills, Penelope Ward, Stephen E. Straus	443
20	Putative Neurotoxicity of SKF 38393 and Other D₁ Dopaminergic Drugs Investigated in Rat Striatum 1992 ·Journal of Neurochemistry ·Lawrence Isaac, Roger Mills, L.J. Fowler, Beryl S. Starr, Michael S. Starr	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact